GlassScriptPhysician profile
Nidhi Mody
NPI 1649765348
$788.55
in general payments reported to CMS, 2019-2025
13 companies · $483 in 2025
The $483 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.95 · 2024: $288 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $235.72 | 2025 | Tremfya |
| Janssen Biotech, INC. | $100.14 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $90.03 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $88.33 | 2024 | |
| Abbvie INC. | $70.24 | 2024-2025 | |
| Glaxosmithkline, LLC. | $39.87 | 2024-2025 | Benlysta |
| Radius Health, INC. | $34.21 | 2025 | |
| Organon LLC | $31.95 | 2024-2025 | Renflexis, Hadlima |
| Ucb, INC. | $31.17 | 2024-2025 | Bimzelx |
| Pfizer INC. | $18.08 | 2024 | |
| Lilly USA, LLC | $17.34 | 2024 | Taltz |
| Esperion Therapeutics, INC. | $16.95 | 2023 | Nexletol |
| Aurinia Pharma U.S., INC. | $14.52 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidhi Mody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.